Nyannie
2021-09-15
Good
PROG Stock: The Big Patent News That Has Biotech Penny Stock Progenity Soaring Today
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":882838620,"tweetId":"882838620","gmtCreate":1631672328560,"gmtModify":1631889928966,"author":{"id":3582719067968878,"idStr":"3582719067968878","authorId":3582719067968878,"authorIdStr":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":24,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/882838620","repostId":1133388737,"repostType":4,"repost":{"id":"1133388737","kind":"news","pubTimestamp":1631670622,"share":"https://www.laohu8.com/m/news/1133388737?lang=&edition=full","pubTime":"2021-09-15 09:50","market":"us","language":"en","title":"PROG Stock: The Big Patent News That Has Biotech Penny Stock Progenity Soaring Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1133388737","media":"investorplace","summary":"Progenity(NASDAQ:PROG) stock is taking off on Tuesday after the company revealed a new patent grante","content":"<p><b>Progenity</b>(NASDAQ:<b><u>PROG</u></b>) stock is taking off on Tuesday after the company revealed a new patent granted to it.</p>\n<p>The patent for Progenity is for its “assessment of preeclampsia using assays for free and dissociated placental growth factor.”This covers methods, compositions, and kits that can detect and measure free and dissociated placental growth factor levels in biological samples.</p>\n<p>This patent is connected to its Preecludia test. The company expects it to reach a $3 billion a year market in the U.S. That includes the laboratory-developed test immunodiagnostic that’s under development. It also has potential as an in vitro diagnostic and point-of-care solution around the world.</p>\n<p>Progenity says that it’s planning for commercialization opportunities to launch the laboratory-developed test in the U.S. It’s also searching out ways to commercialize the in vitro diagnostic test across the globe.</p>\n<p>Matthew Cooper, PhD, chief scientific officer of Progenity, said this about the news boosting PROG stock up today.</p>\n<blockquote>\n “We are pleased the USPTO has granted this patent covering unique and novel methods for determining levels of free and dissociated PlGF, since detection and quantification of both biomarkers are critical for assessing preeclampsia. This discovery helped drive the excellent performance we observed in our clinical verification and validation studies.”\n</blockquote>\n<p>PROG stock is seeing heavy trading alongside today’s patent news. As of this writing, more than 43 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 5.7 million shares.</p>\n<p>PROG stock was up 14.7% as of Tuesday afternoon.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PROG Stock: The Big Patent News That Has Biotech Penny Stock Progenity Soaring Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPROG Stock: The Big Patent News That Has Biotech Penny Stock Progenity Soaring Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 09:50 GMT+8 <a href=https://investorplace.com/2021/09/prog-stock-the-big-patent-news-that-has-biotech-penny-stock-progenity-soaring-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Progenity(NASDAQ:PROG) stock is taking off on Tuesday after the company revealed a new patent granted to it.\nThe patent for Progenity is for its “assessment of preeclampsia using assays for free and ...</p>\n\n<a href=\"https://investorplace.com/2021/09/prog-stock-the-big-patent-news-that-has-biotech-penny-stock-progenity-soaring-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/09/prog-stock-the-big-patent-news-that-has-biotech-penny-stock-progenity-soaring-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133388737","content_text":"Progenity(NASDAQ:PROG) stock is taking off on Tuesday after the company revealed a new patent granted to it.\nThe patent for Progenity is for its “assessment of preeclampsia using assays for free and dissociated placental growth factor.”This covers methods, compositions, and kits that can detect and measure free and dissociated placental growth factor levels in biological samples.\nThis patent is connected to its Preecludia test. The company expects it to reach a $3 billion a year market in the U.S. That includes the laboratory-developed test immunodiagnostic that’s under development. It also has potential as an in vitro diagnostic and point-of-care solution around the world.\nProgenity says that it’s planning for commercialization opportunities to launch the laboratory-developed test in the U.S. It’s also searching out ways to commercialize the in vitro diagnostic test across the globe.\nMatthew Cooper, PhD, chief scientific officer of Progenity, said this about the news boosting PROG stock up today.\n\n “We are pleased the USPTO has granted this patent covering unique and novel methods for determining levels of free and dissociated PlGF, since detection and quantification of both biomarkers are critical for assessing preeclampsia. This discovery helped drive the excellent performance we observed in our clinical verification and validation studies.”\n\nPROG stock is seeing heavy trading alongside today’s patent news. As of this writing, more than 43 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 5.7 million shares.\nPROG stock was up 14.7% as of Tuesday afternoon.","news_type":1},"isVote":1,"tweetType":1,"viewCount":232,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/882838620"}
精彩评论